On March 29, 2021 Theralase Technologies Inc. ("Theralase" or the "Company") (TSXV: TLT) (OTCQB: TLTFF), a clinical stage pharmaceutical company focused on the research and development of light activated Photo Dynamic Compounds ("PDC") and their associated drug formulations used to safely and effectively destroy various cancers, bacteria and viruses reported the launch of the Theralase Anti-Cancer Therapy ("ACT") research centre located within the Li Ka Shing Knowledge Institute of St. Michael’s Hospital, Unity Health Toronto, effective April 1, 2022, relocating its research team from University Health Network ("UHN"), Toronto (Press release, Theralase, MAR 29, 2021, View Source [SID1234577272]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The Li Ka Shing Knowledge Institute of St. Michael’s is home to leading researchers, educators and clinicians — dedicated professionals making new scientific discoveries, generating novel therapies, developing innovative training programs and helping translate knowledge into practice.
The ACT research centre is a fully equipped laboratory dedicated exclusively to Theralase ACT research and development as it advances towards commercialization with its lead PDC, TLD-1433, as well as its systemic and targeted formulation – Rutherrin. A Partnership with the Li Ka Shing Knowledge Institute of Unity Health provides access to additional expertise, advisory networks and opportunities to accelerate product development and commercialization.
Dr. Ori Rotstein MD, Msc., Vice President of Research and Innovation at Unity Health, Professor and Associate Chair of the Department of Surgery at University of Toronto welcomed Theralase stating, "Our research facilities uniquely align scientific, clinical and business initiatives, which helps to accelerate our partners’ path to market by validating their solutions directly in the healthcare setting starting at the research bench and culminating to clinical studies."
Michael Jewett MD, FRCSC, FACS, CM, Departments of Surgery (Urology), University of Toronto and Chair, Theralase Medical and Scientific Advisory Board, stated "I am delighted by the research and clinical milestones that the Theralase team has been able to achieve in advancing its PDC technology, including, launching a Phase II Non-Muscle Invasive Bladder Cancer ("NMIBC") pivotal clinical study in Canada and the US. In 2021, Theralase plans to complete the non-Good Laboratory Practice ("GLP") and GLP toxicology of Rutherrin (TLD-1433 combined with transferrin) to be used as a radiosensitizer in the treatment of multiple solid tumor types: including Glio-Blastoma Muliforme ("GBM") and Non-Small Cell Lung Cancer ("NSCLC") among others. As Theralase advances in its research with Rutherrin it makes sense for the Company to launch its own independent research centre focused on this evolving technology."
Lothar Lilge Ph.D., Senior Scientist Princess Margaret Cancer Centre, UHN, stated "I am pleased that Theralase has graduated to its own independent research center. I will continue to support the Company in the research of light activated PDC therapy and Monte Carlo simulation."
Arkady Mandel, M.D., Ph.D., D.Sc., Chief Scientific Officer, Theralase stated that, "Launching the Theralase ACT Research Centre at Unity Health aids in the translation of our cutting-edge scientific and pre-clinical research. Given the outstanding range of bactericidal, viral and cancer cell kill rates the Company has achieved to date, it has become clear there are opportunities abounding to expand our scientific horizons through collaborative arrangements in many diverse and exciting new clinical applications. The current pandemic of COVID-19 occurring world-wide reminds us how vulnerable we are to new infectious diseases and why new advanced and innovative technologies that combat such infectious agents are seriously needed. The Theralase TLD-1433 and Rutherrin technologies and patented medical laser systems are just such an innovation in the battle against cancer and infections, which claim countless lives every day world-wide. The Company now has an exceptional platform to continue an expanded laboratory research program as it actively advances the pivotal Phase II NMIBC clinical study to enroll and treat patients inflicted with Bacillus Calmette Guerin ("BCG")-Unresponsive Carcinoma In-Situ ("CIS") or who are intolerant to BCG Therapy ("Study II") and prepares for Good Laboratory Practices ("GLP") toxicology testing of Rutherrin in 4Q21."